share_log

Canaccord Genuity Maintains Buy on Hims & Hers Health, Raises Price Target to $38

Canaccord Genuity Maintains Buy on Hims & Hers Health, Raises Price Target to $38

凱納格美證券維持買入命令,目標價提高至38美元
Benzinga ·  12/02 22:19  · 評級/大行評級

Canaccord Genuity analyst Maria Ripps maintains Hims & Hers Health (NYSE:HIMS) with a Buy and raises the price target from $28 to $38.

Canaccord Genuity分析師Maria Ripps維持Hims & hers Health(紐交所:HIMS)的買入評級,並將目標價格從28美元上調至38美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論